Read our latest updates & insights

On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions included:

Novo Nordisk’s Wegovy® (semaglutide) – PBAC refused PBS-listing for severe obesity;

On 15 March 2024, CuraTeQ Biologics (a subsidiary of Aurobindo) announced that it successfully completed phase I trials for omalizumab biosimilar (BP11), demonstrating pharmacokinetic and pharmacodynamic equivalence to Genentech’s/Novartis’ US and EU-sourced Xolair®.  The t...

On 14 March 2024, Biocon Biologics announced that it has entered a long-term commercial collaboration with Eris Lifesciences, including to increase access to its biosimilars in India.  The deal, worth INR 12,420 million, involves a 10-year supply agreement with Eris and ove...

On 14 March 2024, AstraZeneca announced that it has entered into an agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.  Amoylt’s portfolio notably includes eneboparatide (AZP-3...

On 13 March 2024, Sandoz reported double-digit growth of 15% in its 2023 biosimilar sales.  Sandoz attributed this growth to the launch of Hyrimoz®(biosimilar to AbbVie’s Humira®,adalimumab)  in the US and entering an agreement to commercialise Samsung Bioepis’ SB17 (biosim...

On 12 March 2024, Regeneron filed notices of appeal in the United States Court of Appeals for the Federal Circuit challenging findings of the Patent Trial and Appeal Board (PTAB) that claims of two of its patents are invalid. The Regeneron patents at issue are 10,130,681 an...